Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain

Sarkar, Arindam; Banik, Avishek; Pathak, Bani Kumar; Mukhopadhyay, Subhra Kanti; Chatterjee, Souvik

doi:10.1186/1471-2334-13-368

Cited by 18 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in the E protein influence cell tropism, virulence, and antigenicity of JEV [15–17]. Amino acid variations in the E protein have been reported between GI and GIII strains [10,18,19], showing an antigenic difference between the two genotypes [20]. Reduced levels of neutralizing antibodies against GI strains have been observed in both humans and pigs vaccinated with GIII-derived vaccines [18,21].…”

Section: Introductionmentioning

confidence: 99%

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

et al. 2019

View full text Add to dashboard Cite

Genotype III (GIII) Japanese encephalitis virus (JEV) predominance has gradually been replaced by genotype I (GI) over the last 20 years in many Asian countries. This genotype shift raises concerns about the protective efficacy of Japanese encephalitis (JE) vaccines, as all of the currently licensed JE vaccines are derived from GIII strains. In this study, we conducted vaccination-challenge protection assays to evaluate the cross-protective efficacy of GI- or GIII-derived vaccines against the challenge of a heterologous genotype using a mouse challenge model. Titration of the neutralizing antibodies elicited by SA14-14-2 live-attenuated JE vaccine (SA14-14-2 vaccine), a GIII-derived vaccine, indicated that the titer of neutralizing antibodies specific to heterologous genotype GI stain was significantly lower than that specific to homologous genotype GIII strain in both pigs and mice immunized with the SA14-14-2 vaccine. Vaccination of mice with SA14-14-2 vaccine or a GIII-inactivated vaccine at high and medium doses completely protected vaccinated mice against challenge with the homologous genotype GIII strains, but failed to provide the vaccinated mice complete protection against the challenge of heterologous genotype GI strains. The protection rates against GI strain challenge were 60%–80%, showing that these vaccines were partially protective against GI strain challenge. Additionally, vaccination of mice with a GI-inactivated vaccine conferred 100% protection against the challenge of homologous genotype GI strains, but 50%–90% protection against the challenge of heterologous genotype GIII strains, showing a reduced protective efficacy of a GI-derived vaccine against GIII strain challenge. Overall, these observations demonstrated a partial cross-protection between GI and GIII strains and suggested a potential need for new JE vaccine strategies, including options like a bivalent vaccine, to control both genotype infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The state of West Bengal is situated at the eastern part of India and the first major outbreak of JE took place in the year 1973 in the two districts of West Bengal, namely Burdwan and Bankura [Sarkar et al, ]. The endemicity of JEV in West Bengal has been proved by earlier publications [Sarkar et al, ,, ]. Although vaccination programs have been conducted against JE in different districts of West Bengal by the State Health Department, Govt.…”

Section: Introductionmentioning

confidence: 99%

Japanese encephalitis associated acute encephalitis syndrome cases in West Bengal, India: A sero‐molecular evaluation in relation to clinico‐pathological spectrum

Sarkar

Datta

Pathak

et al. 2015

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Japanese encephalitis (JE) is a major public health problem in Asia and worldwide and it is responsible mainly for viral acute encephalitis syndrome (AES). The sole etiologic agent of JE is Japanese encephalitis virus (JEV). Although JE/AES cases have been regarded traditionally as a disease of children, a growing number of patients with JE/AES cases are also seen in the adult age group every year in the state of West Bengal, India in spite of vaccination. Therefore, a systematic study was performed to differentiate and characterize the clinico-pathological parameters and viral diversity among the patients of different age groups. Viral diversity was also evaluated from the JE/AES cases, depending on their disease severity. A total of 441 JE/AES cases were included in this study. By MAC-ELISA, 111 samples were found JEV IgM positive and among the IgM negative cases, 26 samples were found RT-PCR positive against JEV infection. Neck rigidity, abnormal behavior, convulsion, protein in CSF, WBC in CSF, and aspartate transaminase in blood differed significantly among the patients of pediatric-adolescent and adult group in both IgM positive and RT-PCR positive cases. Viral diversity was increased significantly in the pediatric-adolescent group compared to adult patients. Interestingly, with the rise in disease severity the viral diversity was found to be increased among the patients, irrespective of their age distribution. Based on clinico-pathological parameters and analysis of viral diversity, it can be concluded that viral diversity which occurs naturally is likely to affect disease severity, especially in the patients of pediatric-adolescent group.

show abstract

“…16 Finally the predicted protein-ligand bindings were visualized with PyMOL software (https://pymol.org/). 17…”

Section: In Silico Studiesmentioning

confidence: 99%

In Silico and in Vitro Studies of Fluorinated Chroman-2-Carboxilic Acid Derivatives as an Anti-tubercular Agent

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Despite the use of traditional method, Ugi reaction currently is a well-established multicomponent reaction. Chromane motif itself possesses a variety of biological functions. In order to improve its anti-tubercular activity, it is necessary to modify it accordingly. Aim: To ensure relation between in silico and in vitro study, we have carried out in vitro screening against H37Rv anti-tubercular agent. Materials and methods: Ugi four-component condensation (U-4CCRs) between 6-fluorochroman-2-carboxylic acid, various aryl aldehyde, 3,4,5-trimethoxy amine and tert-butyl isocyanide, gave N-((tert-butylcarbamoyl)(4-substitutedphenyl) methyl)-6-fluoro-N-(3,4,5-trimethoxyphenyl) chroman-2-carboxamide. The molecular level insight of all compounds was carried out by molecular docking study against the receptor tyrosine phosphatase PtpB. All these newly synthesized compounds were screened for their anti-microbial activity against Mycobacterium tuberculosis H37Rv to determine the MIC, IC50 and IC90 of the compound. Results: The compound 5d also shows large hydrophobic surface contact on the face of the α7–α8 (Ile 207, Phe 211, Met 206, Ile203, Phe161, Phe80, Met126, Tyr130, Val231 and Leu101) that lines one side of the entrance to the active site of the receptor. The compound 5d bind with tyrosine phosphatase PtpB with predicted docking geometric score of 4664, whereas a score of rifampicin was 6586 determined. Conclusion: From the docking studies, compound 5d, was considered to be the potent inhibitor, which gave strong supportive coordinate with the in vitro study. It is highly active against H37Rv, having MIC and IC50 value of was 70 μM and 53 μM respectively in in vitro study.

show abstract

Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain

Cited by 18 publications

References 41 publications

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

Japanese encephalitis associated acute encephalitis syndrome cases in West Bengal, India: A sero‐molecular evaluation in relation to clinico‐pathological spectrum

In Silico and in Vitro Studies of Fluorinated Chroman-2-Carboxilic Acid Derivatives as an Anti-tubercular Agent

Contact Info

Product

Resources

About